A physiological pharmacokinetic model describing the disposition of lycopene in healthy men

Author(s): Diwadkar-Navsariwala V, Novotny JA, Gustin DM, Sosman JA, Rodvold KA, et al.

Abstract

A physiological pharmacokinetic model was developed to describe the disposition of lycopene, delivered as a tomato beverage formulation in five graded doses (10, 30, 60, 90, or 120 mg), for a phase I study in healthy male subjects (five per dose). Blood was collected before dose administration (0 h) and at scheduled intervals until 672 h. Serum concentrations of carotenoids and vitamins were measured by high performance liquid chromatography analysis. The model was comprised of seven compartments: gastrointestinal tract, enterocytes, chylomicrons, plasma lipoproteins, fast-turnover liver, slow-turnover tissues, and a delay compartment before the enterocytes. As predicted, the percent absorption at the 10 mg dose (33.9 +/- 8.1%) was significantly greater than at the higher doses; however, the amount of lycopene absorbed (mg) was not statistically different (mean: 4.69 +/- 0.55 mg) between doses, suggesting a possible saturation of absorptive mechanisms. The slow-turnover tissue compartment served as a slow-depleting reservoir for lycopene, and the liver represented the fast-turnover pool. Independent of dose, 80% of the subjects absorbed less than 6 mg of lycopene. This may have important implications for planning clinical trials with pharmacological doses of lycopene in cancer control and prevention if absorption saturation occurs at levels that are already being consumed in the population.

Similar Articles

Role of lycopene and tomato products in prostate health

Author(s): Stacewicz-Sapuntzakis M, Bowen PE

Plant extracts: sense or nonsense?CurrOpinUrol 18: 16-20

Author(s): Madersbacher S, Berger I, Ponholzer A, Marszalek M

Lycopene inhibits the growth of normal human prostate epithelial cells in vitro

Author(s): Obermüller-Jevic UC,Olano-Martin E, Corbacho AM, Eiserich JP, van der Vliet A, et al.

Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate

Author(s): Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, et al.

Lycopene inhibits disease progression in patients with benign prostate hyperplasia

Author(s): Schwarz S,Obermüller-Jevic UC, Hellmis E, Koch W, Jacobi G, et al.

Diet adherence dynamics and physiological responses to a tomato product whole-food intervention in African-American men

Author(s): Park E,Stacewicz-Sapuntzakis M, Sharifi R, Wu Z, Freeman VL, et al.

Lycopene and prostate cancer

Author(s): Barber NJ, Barber J

Tomatoes, lycopene, and prostate cancer: progress and promise

Author(s): Hadley CW, Miller EC, Schwartz SJ, Clinton SK

A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste

Author(s): Richelle M,Bortlik K, Liardet S, Hager C, Lambelet P, et al.

Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas

Author(s): Canene-Adams K,Lindshield BL, Wang S, Jeffery EH, Clinton SK, et al.

Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice

Author(s): Limpens J,Schröder FH, de Ridder CM, Bolder CA, Wildhagen MF, et al.

Chemoprevention of prostate cancer with lycopene in the TRAMP model

Author(s): Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, et al.

Antioxidants block prostate cancer in lady transgenic mice

Author(s): Venkateswaran V,Fleshner NE, Sugar LM, Klotz LH

Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer

Author(s): Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, et al.

Lycopene effects on rat normal prostate and prostate tumor tissue

Author(s): Siler U, Herzog A, Spitzer V, Seifert N, Denelavas A, et al.

Effects of lycopene on protein expression in human primary prostatic epithelial cells

Author(s): Qiu X, Yuan Y, Vaishnav A, Tessel MA, Nonn L, et al.

Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines

Author(s): Teodoro AJ, Oliveira FL, Martins NB, Maia Gde A, Martucci RB, et al.

A prospective study of lycopene and tomato product intake and risk of prostate cancer

Author(s): Kirsh VA,Mayne ST, Peters U, Chatterjee N, Leitzmann MF, et al.

Lycopene for the prevention of prostate cancer

Author(s): Ilic D, Forbes KM, Hassed C

A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk

Author(s): Bunker CH, McDonald AC, Evans RW, de la Rosa N, Boumosleh JM, et al.

Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis

Author(s): Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, et al.

Serenoarepens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH

Author(s): Morgia G, Russo GI, Voce S, Palmieri F, Gentile M, et al.